Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cholecalciferol/raloxifene - Addpharma

Next Previous
Search
Drug Profile

Cholecalciferol/raloxifene - Addpharma

Alternative Names: AD-102

Latest Information Update: 24 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Addpharma
  • Class Adjuvants; Antineoplastics; Calcium regulators; Cholestenes; Osteoporosis therapies; Small molecules; Sterols; Stilbenes; Vitamin D analogues
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Postmenopausal osteoporosis

Most Recent Events

  • 24 Jan 2023 Cholecalciferol/raloxifene is still in preregistration for Postmenopausal osteoporosis in South Korea (PO) (Addpharma pipeline, January 2023)
  • 17 Dec 2020 Cholecalciferol/raloxifene - Addpharma is available for licensing as of 17 Dec 2020. http://www.addpharma.co.kr/
  • 01 Nov 2020 Preregistration for Postmenopausal osteoporosis in South Korea (PO) (Addpharma pipeline, December 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top